§ Mr. Ashleyasked the Secretary of State for Social Services if the United States Food and Drug Administration informed the Committee on Safety of Medicines of its intention to reprimand Glaxo for allegedly making unsubstantiated claims about Zantac; if the Committee on Safety of Medicines has discussed. the marketing of the drug; and if the Committee has expressed to Glaxo any reservations about its marketing in general and its advertising in particular.
§ Mr. HayhoeNeither my Department nor the Committee on Safety of Medicines has heard from the United States Food and Drug Administration directly about the promotion in the States of the drug Zantac. I have seen no evidence to suggest that this drug is being improperly marketed in the United Kingdom. However, if the right hon. Member has any evidence to the contrary, I will be glad to consider it.